Silvia Rosanna Casati

Dr. Silvia Rosanna Casati

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 March 2024 in Cells
Verified
Journal Article
Open access
PDF file
SCSilvia Rosanna Casati
Silvia Rosanna Casati
DCDavide Cervia
Davide Cervia
PRPaulina Roux-Biejat
Paulina Roux-Biejat
Claudia MoscheniClaudia Moscheni
Claudia Moscheni
Cristiana PerrottaCristiana Perrotta
Cristiana Perrotta
Clara De PalmaClara De Palma
Clara De Palma
Duchenne muscular dystrophy (DMD) is a genetic progressive muscle-wasting disorder that leads to rapid loss of mobility and premature death. The absence of functional dystrophin in DMD patients reduces sarcolemma stiffness and increases contraction damage, triggering a cascade of events leading to muscle cell degeneration, chronic inflammation, and deposition of fibrotic and adipose tissue. Efforts in the last decade have led to the clinical approval of novel drugs for DMD that aim to restore dystrophin function. However, combination therapies able to restore dystrophin expression and target the myriad of cellular events found impaired in dystrophic muscle are desirable. Muscles are higher energy consumers susceptible to mitochondrial defects. Mitochondria generate a significant source of reactive oxygen species (ROS), and they are, in turn, sensitive to proper redox balance. In both DMD patients and animal models there is compelling evidence that mitochondrial impairments have a key role in the failure of energy homeostasis. Here, we highlighted the main aspects of mitochondrial dysfunction and oxidative stress in DMD and discussed the recent findings linked to mitochondria/ROS-targeted molecules as a therapeutic approach. In this respect, dual targeting of both mitochondria and redox homeostasis emerges as a potential clinical option in DMD.

14 April 2023 in Cytotherapy
Verified
Journal Article
Open access
CGChiara Giannasi
Chiara Giannasi
SNStefania Niada
Stefania Niada
EMElena Della Morte
Elena Della Morte
SCSilvia Rosanna Casati
Silvia Rosanna Casati
Clara De PalmaClara De Palma
Clara De Palma
ABAnna Teresa Brini
Anna Teresa Brini
A large part of mesenchymal stromal cell (MSC) regenerative and immunomodulatory action is mediated by paracrine signaling. Hence, an increasing body of evidence acknowledges the potential of MSC secretome in a variety of preclinical and clinical scenarios. Mid-term serum deprivation is a common approach in the pipeline of MSC secretome production. Nevertheless, up to now, little is known about the impact of this procedure on the metabolic status of donor cells. Here, through untargeted differential metabolomics, we revealed an impairment of mitochondrial metabolism in adipose-derived MSCs exposed for 72 h to serum deprivation. This evidence was further confirmed by the significant accumulation of reactive oxygen species and the reduction of succinate dehydrogenase activity. Probably as a repair mechanism, an upregulation of mitochondrial superoxide dismutase was also induced. Of note, the analysis of mitochondrial functionality indicated that, despite a significant reduction of basal respiration and ATP production, serum-starved MSCs still responded to changes in energy demand. This metabolic phenotype correlates with the obtained evidence of mitochondrial elongation and branching upon starvation.

7 April 2025 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
Matteo GiovarelliMatteo Giovarelli
Matteo Giovarelli
SZSilvia Zecchini
Silvia Zecchini
SCSilvia Rosanna Casati
Silvia Rosanna Casati
LLLaura Lociuro
Laura Lociuro
OGOriola Gjana
Oriola Gjana
Clara De PalmaClara De Palma
Clara De Palma
Duchenne muscular dystrophy (DMD) is a devastating genetic disorder, whose management is still a major challenge, despite progress in genetic and pharmacological disease-modifying treatments have been made. Mitochondrial dysfunctions contribute to DMD, however, there are no effective mitochondrial therapies for DMD. SIRT1 is a NAD+-dependent deacetylase that controls several key processes and whose impairment is involved in determining mitochondrial dysfunction in DMD. In addition to well-known resveratrol, other potent selective activators of SIRT1 exist, with better pharmacokinetics properties and a safer profile. Among these, SRT2104 is the most promising and advanced in clinical studies. Here we unveil the beneficial effects of SRT2104 in flies, mice, and patient-derived myoblasts as different models of DMD, demonstrating an anti-inflammatory, anti-fibrotic, and pro-regenerative action of the drug. We elucidate, by molecular dynamics simulations, that a conformational selection mechanism is responsible for the activation of SIRT1. Further, the impact of SRT2104 in reshaping muscle proteome and acetylome profiles has been investigated, highlighting effects that mimic those induced by exercise. Overall, our data suggest SRT2104 as a possible therapeutic candidate to successfully counteract DMD progression.

Verified
Journal Article
Open access
PDF file
Maria FazzariMaria Fazzari
Maria Fazzari
Giulia LunghiGiulia Lunghi
Giulia Lunghi
Emma Veronica CarsanaEmma Veronica Carsana
Emma Veronica Carsana
MVManuela Valsecchi
Manuela Valsecchi
ESEleonora Spiombi
Eleonora Spiombi
ECElena Chiricozzi
Elena Chiricozzi
Rett syndrome (RTT) is a severe neurodevelopmental disorder primarily caused by mutations in the methyl-CpG binding protein 2 (MECP2) gene. Despite advancements in research, no cure exists due to an incomplete understanding of the molecular effects of MeCP2 deficiency. Previous studies have identified impaired tropomyosin receptor kinase (Trk) neurotrophin (NTP) signaling and mitochondrial redox imbalances as key drivers of the pathology. Moreover, altered glycosphingolipid metabolism has been reported in RTT. GM1 ganglioside is a known regulator of the nervous system, and growing evidence indicates its importance in maintaining neuronal homeostasis via its oligosaccharide chain, coded as GM1-OS. GM1-OS directly interacts with the Trk receptors on the cell surface, triggering neurotrophic and neuroprotective pathways in neurons. In this study, we demonstrate that GM1-OS ameliorates RTT deficits in the Mecp2-null model. GM1-OS restored synaptogenesis and reduced mitochondrial oxidative stress of Mecp2-knock-out (ko) cortical neurons. When administered in vivo, GM1-OS mitigated RTT-like symptoms. Our findings indicate that GM1-OS effects were mediated by Trk receptor activation on the neuron’s plasma membrane. Overall, our results highlight GM1-OS as a promising candidate for RTT treatment.

8 March 2026 in Research Square
Verified
Preprint
Open access
PDF file
Clara De PalmaClara De Palma
Clara De Palma
SCSilvia Rosanna Casati
Silvia Rosanna Casati
SZSilvia Zecchini
Silvia Zecchini
CGChristel Gentil
Christel Gentil
OGOriola Gjana
Oriola Gjana
SFSESTINA FALCONE
SESTINA FALCONE
Mitochondrial dysfunction is an early pathogenic event in dystrophic muscle contributing to muscle damage. Here, we provide an in-depth characterization of the marked induction of mitochondrial fission in mdx muscle fibers, driven by excessive activation of the fission regulator Drp1. This aberrant Drp1 activity triggers the integrated stress response (ISR), resulting in muscle-derived secretion of FGF21, which in turn promotes the fibro-adipogenic differentiation of fibro-adipogenic progenitors (FAPs). Importantly, we demonstrate that inhibition of Drp1 is both necessary and sufficient to restore mitochondrial function and suppresses FGF21 upregulation, limiting its detrimental impact on FAPs and contributing to the overall improvement of DMD phenotype. Our study identifies FGF21 as a key mediator of DMD pathology and supports targeting mitochondrial dynamics as a disease-modifying therapeutic strategy.